Pharmaceutical Investing Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pharmaceutical Investing ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
Pharmaceutical Investing Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
Pharmaceutical Investing European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
Pharmaceutical Investing ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis under the Non-Insured Health Benefits Program
Pharmaceutical Investing Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
Life Science Investing Arvinas and Pfizer Announce Upcoming Vepdegestrant Poster Presentations at the 2023 European Society for Medical Oncology Breast Cancer Annual Congress
Life Science Investing XTANDI® plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide
Life Science Investing U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
Juggernaut Further Increases Oversubscribed Financing to $9,557,000 due to Tremendous Strong Demand from Institutions and Accredited Investors
CoTec Holdings Corp. To Commence Expansion Drilling Program And Secure A Salter Techology Bulk Sample At The Lac Jeannine Property
